Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. State Street (STT) downgraded to Hold from Buy at Deutsche Bank with analyst Brian Bedell saying the new macro backdrop is unfavorable for trust banks given exposure to lower long-term bond yields and lower short-term rates. 2. Moderna (MRNA) downgraded to Neutral from Buy at BofA with analyst Geoff Meacham stating the company's year-to-date stock price run-up of 40.5% is driven by its mRNA-1273 efforts on coronavirus, which he does not expect to be de-risked for some time. 3. Check Point (CHKP) downgraded to Sell from Neutral at Goldman Sachs with analyst Brian Essex saying Channel surveys have consistently reflected share loss for Check Point and recent checks at the RSA Conference implied a lack of improvement. 4. Zoom Video (ZM) downgraded to Equal Weight from Overweight at Stephens with analyst Ryan MacWilliams stating he thinks the company's current valuation prices in his bullish outlook. 5. Splunk (SPLK) downgraded to Neutral from Buy at Monness Crespi with analyst Brian White stating that he prefers a more cautious stance as Splunk undergoes a more aggressive cloud transition and "the macroeconomic backdrop grows more ominous by the day." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Welcome to "#SocialStocks," The Fly's weekly recap of Wall Street's reactions to social media stock news.  TIK TOK BAN... To see the rest of the story go to thefly.com. See Story Here

Moderna and OpenAI announced their ongoing collaboration to co-innovate with a shared vision of AI's transformative potential in the future of business and healthcare. Moderna is a digital-first company that has leveraged the power of machine learning since its beginnings. This strong data foundation, along with its robust culture of learning, positions the Company to responsibly and seamlessly integrate generative AI into its operations and capitalize on next-generation AI innovation. The organizations began their collaboration in early 2023 with the launch of Moderna's own instance of ChatGPT, called mChat, which was internally built on top of OpenAI's API. With more than 80% internal adoption since its debut, this initial success accelerated an AI culture that led to the deployment of ChatGPT Enterprise and its enhanced capabilities such as Advanced Analytics, Image Generation and GPTs. These GPTs are now embedded across Moderna's business functions - from legal, to research, to manufacturing, to commercial - and are purpose-built as assistants that work beside Moderna's employees, augmenting their roles through personalized support. With these tools serving as an extension to Moderna's team, the Company can advance its mission to deliver the greatest possible impact to people through mRNA medicines.

New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).

Moderna announced a contract with the Ministry of Health in Brazil to supply its mRNA COVID-19 vaccine as an integral part of Brazil's 2024 national vaccination campaign against COVID-19. This contract follows the Brazilian Health Regulatory Agency's approval of Moderna's COVID-19 vaccine in March 2024, which encodes the spike protein of the XBB.1.5 sublineage of SARS-CoV-2 for active immunization for the prevention of COVID-19 in children from six months of age and adults. Under the contract, 12.5 million doses of Moderna's mRNA COVID-19 vaccine are anticipated for delivery in the second quarter of 2024, marking a significant milestone in Brazil's ongoing efforts to combat COVID-19. The partnership between Moderna and the Ministry of Health reflects a shared commitment to public health and the importance of national immunization campaigns. This contract is expected to bolster Brazil's national vaccination campaign and contribute to the global effort to combat the enduring threat of COVID-19.